HaemaLogiX's Tertia Dex explains the KappaMab antibody Posted on August 29th, 2022 . Updated on May 9th, 2023 by Paul LangleyHaemaLogix's Chief Manufacturing and Development Officer, Tertia Dex, explains the fascinating process to manufacture KappaMab, a highly-targeted antibody designed to treat mutliple myeloma.